CRISPR Therapeutics' (CRSP) CFO recently resigned, potentially signaling that CRSP stock could be heading for a downturn. Further, the shares are changing hands at an exorbitant valuation, while most of the company's drugs will likely not complete late-stage trials for many years. Given these points, investors should think about unloading CRISPR's shares.
